Scholars Central

Conference abstractPublished 7 Dec 2016

Higher efficacy of sequential therapy with pegylated interferon-alpha 2b and tenofovir compared to tenofovir monotherapy in HBeAg positive chronic hepatitis B patients

Authors: Ankur Jindal, Manoj Sharma, Shiv K Sarin

Institute of Liver and Biliary Sciences, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Monotherapy with PEG-interferon (PEG-IFN-Ã?±) or nucleotide analogues (NA) are largely ineffective in chronic hepatitis B (CHB) patients. A sequential combination therapy may have better therapeutic effects by sustained viral suppression combined with immunomodulation. Aim: To Study the high efficacy of sequential therapy with pegylated interferon-alpha 2b and tenofovir compared to tenofovir monotherapy in HBeAg positive chronic hepatitis B patients. Methods: One hundred twenty six treated naive HBeAg (+) CHB patients with moderately elevated alanine aminotransferase (ALT) (48-200 IU/mL) received tenofovir 300 mg/day for 72 weeks with PEG-IFN-a2b 1.5 mcg/kg per week added after first 12 weeks (lead-in-period) for 24 weeks (sequential combination therapy; ST) or tenofovir monotherapy; 300 mg/day for 72 weeks (TM). Primary end point was rate of HBeAg loss. Biochemical and virological responses were assessed at weeks 12, 36, 48 and 72 weeks. Combined virological response (CVR) [HBeAg loss and HBV DNA 3Log HBV DNA reduction at week 36 (92.5%) compared to TM group (66%) (P=0.001). Four (7.5%) patients on ST achieved HBsAg loss compared with MT (1 patient, 1.8%) by week 72. No patient had treatment related major adverse effect requiring discontinuation of therapy. Conclusion: 24 weeks of PEG-IFNa2b as add-on sequential regimen to TDF is safe and resulted in more HBeAg and HBsAg loss, when compared to TDF monotherapy in selected HBeAg (+) chronic hepatitis B patients. Long-term follow-up trials are needed to assess for sustained durable response.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Gastrointestinal & Digestive System
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Ankur Jindal”
  • BylineArticles whose byline prints “Manoj Sharma”
  • BylineArticles whose byline prints “Shiv K Sarin”